Is no FDA news bad news for Mesoblast shares?

Where is the FDA update?

| More on:
A health professional wearing a stethoscope and scrubs shrugs with uncertainty.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When it comes to earnings season, no news is good news. That's because if a company is going to fall meaningfully short of its guidance, it has an obligation to inform the market as soon as it knows. This means that the lack of news is usually a good sign.

However, could the same be said for Mesoblast Ltd (ASX: MSB) this week while it awaits the biggest news in its history? That's unclear.

What's going on with Mesoblast shares?

Mesoblast shares were put in a trading halt yesterday pending the release of the results of the U.S. Food and Drug Administration's (FDA) review of its Biologics License Application (BLA) resubmission for remestemcel-L.

Remestemcel-L is a cellular therapy product that consists of cultured, cryopreserved mesenchymal stem cells derived from the bone marrow of healthy donors.

Mesoblast is hoping to gain approval for the treatment of children with steroid-refractory acute graft versus host disease (aGVHD). This is where donor cells (the graft) attack the organs and tissues of the patient who received them.

It has been a rocky road to this point, with the US FDA seemingly very reluctant to approve the treatment. However, Mesoblast has been working incredibly hard to prove that remestemcel-L is the treatment that steroid-refractory aGVHD sufferers need. And given that there are no current approved treatment options for children, the word need is an understatement.

Has the FDA made its decision?

The last update on the matter was that the US FDA would guarantee a decision on the company's BLA resubmission by 2 August (US time). Is the lack of an update bad news?

That's hard to say. But given that the US FDA has listed one approval on its website for 2 August, and not remestemcel-L, things are admittedly looking ominous for the company and its shareholders.

Could the company be preparing an announcement explaining the rejection and its next steps? It seems unlikely that a positive outcome announcement would take long to get out to the market.

However, it is only approaching 6pm in California, so the FDA could be working overtime and may not have even given its verdict yet.

For now, it is all speculation. All should be revealed tomorrow when Mesoblast makes its announcement. Here's hoping for a good decision for shareholders and sufferers of steroid-refractory aGVHD.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »